Skip to main content
SpringerPlus

Table 3 Serum measurements

From: A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma

 

Entire group(N = 32)

Stage IV(N = 22)

Stage III(N = 10)

LDH U/L (Median, Q1, Q3)

223.50, 199.25, 263.75

230.00, 211.50, 307.50

200.00, 171.50, 245.50

VEGF pg/mL (Mean ± SD)

400.40 ± 252.88

422.69 ± 294.45

351.37 ± 118.71

Treg % (Mean ± SD)

27.13 ± 6.15

27.56 ± 6.43

26.18 ± 5.68

Th1/Th2 (Mean ± SD)

0.62 ± 0.17

0.64 ± 0.15

0.58 ± 0.20

CD4/CD8 (Median, Q1, Q3)

1.70, 1.22, 2.14

1.76, 1.01, 2.19

1.65, 1.32, 2.05

  1. LDH, lactic acid dehydrogenase; Q1, first quartile; Q3, third quartile; VEGF, vascular endothelial growth factor; SD, standard deviation; Treg, regulatory T cell.
  2. Table 2: Q1 = first quartile, Q3 = third quartile, SD – standard deviation.
Back to article page